DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3nmd9r/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development - Partial List
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AbbVie Inc.
- Alchemia Limited
- Amgen Inc.
- Aposense Ltd.
- Array BioPharma Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- AVEO Pharmaceuticals, Inc.
- Bayer AG
- BIND Therapeutics, Inc.
- Blend Therapeutics, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cantex Pharmaceuticals, Inc.
- Celator Pharmaceuticals, Inc.
- CellAct Pharma GmbH
- Cerulean Pharma, Inc.
- Cornerstone Pharmaceuticals, Inc.
- Critical Outcome Technologies Inc.
- CytRx Corporation
- Eisai Co., Ltd.
- Eli Lilly and Company
- Exelixis, Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Hutchison MediPharma Limited
- ImmunoCellular Therapeutics, Ltd.
- Immunomedics, Inc.
-
Inbiopro Solutions Pvt. Ltd
For more information visit http://www.researchandmarkets.com/research/3nmd9r/smallcell_lung
